Our Success Stories

Smarter healthcare decisions powered by data: Discover our AI-driven use cases

Real-World Evidence, Real-World Impact

Whether you’re a clinician, data lead, market access strategist, or corporate development lead, explore how we’ve helped teams like yours unlock the full value of their data — and transform it into better decisions.

Clinical & Medical

Data & Digital

Access & Regulatory

Corporate Development

Clinical & Medical

Infectious Diseases

Identifying Drivers of Self-Diagnosis to Enable Over-The-Counter (OTC) Switch

See details

Rare Diseases

Predicting the Progression of a Rare Disease

See details

Cardiovascular Diseases

Optimizing Care Pathways for Heart Failure Patients

See details

Infectious Diseases

Identifying Drivers of Self-Diagnosis  to Enable OTC Switch

 Discover how AI helped define differentiating symptoms to support OTC switch approval

Challenge

Indistinct Symptom Profiles: Easy self-diagnosis is critical for OTC switch, but symptoms overlap with other infectious diseases
Need for Diagnostic Precision: Facilitate accurate self-diagnosis and define early disease onset

Our Solution

Machine Learning on Real-World Data: Classification models with interpretability layers to identify key self-diagnosable symptoms

Results and Impact

Identified 9 differentiating symptoms enabling self-diagnosis
Provided actionable insights provided supporting regulatory application for OTC switch

Rare Diseases

Predicting the Progression of a Rare Disease

Explore how we stratified patients with a rare disease to inform the optimal initiation of treatment

Challenge

Variable Disease Phenotypes: This rare disease manifests in diverse phenotypes, leading to early or late progression
Need for Early Intervention: Identification of patients at risk of rapid decline to guide timely treatment initiation

Our Solution

Applied Data-Driven Disease Modeling using Real-World Data to stratify patients by progression speed and detect early markers of accelerated disease

Results and Impact

Enabled personalized treatment initiation strategies
Identified turning points for disease acceleration
Supported RCT design optimization through disease trajectory simulation

Cardiovascular Diseases

Optimizing Care Pathways  for Heart Failure Patients

 See how we optimized HF patient stratification to inform care pathways using real-world evidence

Challenge

Variable Disease Progression: Heart failure progression varies significantly, complicating therapeutic pathways 
Need for Tailored Care: Precisely segment patients to align care strategies with clinical and economic goals

Our Solution

Data-Driven Clustering: Applied clustering algorithms on US claims data 
Phenotype Stratification: Identified clinically relevant HF phenotypes based on comorbidities and progression patterns

Results and Impact

Discovered 6 unique HF patient phenotypes with distinct comorbidities and hospitalization risks
Provided actionable segmentation for clinical decision-making and targeted interventions

Access & Regulatory

Cardiovascular Diseases

Simulating Real-World Effectiveness for a New Therapy

See details

Rare Diseases

Extending Randomized Controlled Trials (RCT) Insights to Real-World Outcomes

See details

Cardiovascular Diseases

Simulating Real-World Effectiveness for a New Therapy

Discover how we projected real-world treatment impact before market adoption

Challenge

New Treatment, Limited Data: A novel therapy had no real-world effectiveness data
Need for Evidence-Based Positioning: Simulate treatment impact to guide best practices and support prescribers and authorities

Our Solution

Hybrid Real-World Data (RWD) - Randomized Controlled Trials (RCT) Modeling: Estimated survival under standard-of-care using RWD, then applied RCT treatment effects under various therapy positioning scenarios

Results and Impact

Confirmed treatment benefits consistent with RCT outcomes
Identified and highlighted a treatment effect modifier
Provided actionable insights on treatment effectiveness pre market

Rare Diseases

Extending Randomized Controlled Trials (RCT) Insights to Real-World Outcomes

 See how we bridged RCT efficacy data to real-world effectiveness to support strategic treatment launch

Challenge

Fragmented Data Sources: Registries and Real-World Data (RWD) catalogs are scattered, making identification and assessment time-consuming
Need for Extended Insights: Understand treatment impact on real-world outcomes to anticipate post-authorization studies and prepare launch strategy

Our Solution

External Control Arm (ECA):

1. Replicated RCT inclusion/exclusion criteria in external databases
2. Weighted ECA to match patient characteristics
3. Estimated treatment effect on selected real-world outcomes

Results and Impact

Implemented automated extraction and structuring from +200k papers, +250 registries, +10k observational studies
Hazard ratio of 0.33 vs. adjusted ECA → 67% risk reduction over time
Provided robust evidence supporting launch and regulatory discussions

Data & Digital

Rare Disease

Standardizing Disease Identification: From Local Efforts to Scalable Solutions

See details

RWD & Registries

AI-Powered Registry Identification

See details

Rare Diseases

Standardizing Disease Identification:  From Local Efforts to Scalable Solutions

See how we built a scalable Rare Disease Framework to accelerate and harmonize rare disease patient identification across regions

Challenge

Identification Bottlenecks: Patient identification in rare diseases is slow and fragmented, especially in emerging markets 
Need for Standardization: Harmonize local initiatives to ensure consistent and scalable patient identification

Our Solution

Rare Disease Framework including best practices, code modules, and packages to standardize and accelerate patient identification

Results and Impact

Reduced project execution time and simplified methodology adoption
Delivered portable code modules for cross-market application
Increased homogeneity in technical practices
Accelerated patient identification consistently across diverse regions

RWD & Registries

AI-Powered Registry Identification

Discover how we streamlined registry identification and assessment to accelerate real-world evidence projects

Challenge

Fragmented Data Sources: Registries and Real-World Data (RWD) catalogs are scattered, making identification and assessment time-consuming
Need for Relevant Selection: Efficiently identify registries fit for purpose and extract actionable metadata
Enhanced Assessment: Reliable information on registry scope and quality is critical for research

Our Solution

AI-Driven Web Tool (Centralized platform to identify, assess, and select registries):

Centralisation: Single access point across RWD catalogs and research databases
Metadata Extraction: LLMs extract registry details (e.g., name, PICOTS) from abstracts
Hybrid Search Engine: Semantic + keyword search identifies the most relevant registries

Results and Impact

Implemented automated extraction and structuring from +200k papers, +250 registries, +10k observational studies
Identified over 10k unique registries in scientific literature
Delivered a web interface simplifying registry exploration
Saved time and improved retrieval, assessment, and actionability of registry data

Corporate Development

Oncology & Immunology

Optimizing Clinical Strategies through Integrated Evidence Generation Planning

See details

Neurology

Rescuing Value from Failed Trials to enable Strategic Acquisitions

See details

Dermatology

Optimizing Asset Strategy using Synthetic Control Arms

See details

Target Identification

Accelerating Deal Prospecting through AI-Powered Target Screening

See details

Oncology & Immunology

Optimizing Clinical Strategies through  Integrated Evidence Generation Planning

 See how we clarified evidence needs and operationalized a robust clinical roadmap to optimize strategic decisions

Challenge

Unclear regulatory and payer requirements
Difficulty prioritizing indications and investments
High uncertainty affecting success and asset value
Fragmented, unaligned evidence activities

Our Solution

Mapped disease landscape and stakeholder needs
Defined a targeted product profile (TPP)
Identified priority gaps and value drivers
Aligned evidence generation with strategic goals
Co-built an operational evidence plan

Results and Impact

Enabled significant enhancement of asset value, reduced uncertainty, and accelerated strategic decisions through a clarified, actionable evidence roadmap

Neurology

Rescuing Value from Failed Trials to enable Strategic Acquisitions

 See how we helped identify undervalued clinical trial assets by extracting actionable insights from failed clinical studies, enabling targeted acquisition decisions

Challenge

Phase III trial failed primary endpoint despite Phase II success
Inconsistent results between phases hard to explain
Lack of clarity on responsive patient subgroups
Risk of missing value in an apparently failed asset

Our Solution

Applied Q-Finder®, a supervised proprietary subgroup discovery algorithm, to explore Phase III data for responder signals
Combined data insights with expert review and literature
Identified responder profiles with strong efficacy and safety
Statistically validated hypotheses to define target subgroups

Results and Impact

Helped reveal clinically meaningful subpopulations, unlocking hidden asset value and enabling confident, value-driven acquisition decisions

Dermatology

Optimizing Asset Strategy using  Synthetic Control Arms

 See how we leveraged external comparators and Real-World Data-driven simulations to clarify asset effectiveness, supporting strategic investment decisions

Challenge

No active comparator in early-phase trials
Hard to assess relative efficacy or positioning
Limited view of competitive landscape and value
Uncertainty about valuation and regulatory strategy

Our Solution

Aligned scope with client’s evidence goals
Mapped external comparators via registry & SLR
Built synthetic control models for comparisons
Ensured HTA-readiness and strategic communication

Results and Impact

Clarified therapeutic positioning, reduced uncertainty, and strengthened valuation and negotiation power for informed deal-making

Target Identification

Accelerating Deal Prospecting  through AI-Powered Target Screening

 See how we accelerated strategic target identification by combining advanced AI-driven technology scouting and data-driven market assessments in an intuitive digital interface

Challenge

Manual and fragmented scouting workflows
Late detection of strategic opportunities
Subjective and inconsistent target evaluation

Our Solution

Built an AI-powered engine for real-time opportunity detection
Developed a multi-criteria scoring system for target qualification
Create a secure, collaborative platform tailored to internal needs
Integrated continuous user feedback to refine recommendations

Results and Impact

Faster and more objective deal sourcing, reduced cycle times, and improved strategic alignment through automated prospecting

Let’s Build
Your Success Story

Whether you’re exploring new ways to generate evidence, simulate strategic scenarios, or scale your data capabilities, get in touch, we’re here to
help.

Our Success Stories

Real-World Evidence, Real-World Impact

Clinical & Medical

Identifying Drivers of Self-Diagnosis to Enable Over-The-Counter (OTC) Switch

Predicting the Progression of a Rare Disease

Optimizing Care Pathways for Heart Failure Patients

Infectious Diseases

Identifying Drivers of Self-Diagnosis to Enable OTC Switch

Challenge

Our Solution

Results and Impact

Rare Diseases

Predicting the Progression of a Rare Disease

Challenge

Our Solution

Results and Impact

Cardiovascular Diseases​

Optimizing Care Pathways for Heart Failure Patients

Challenge

Our Solution

Results and Impact

Access & Regulatory

Simulating Real-World Effectiveness for a New Therapy

Extending Randomized Controlled Trials (RCT) Insights to Real-World Outcomes

Cardiovascular Diseases

Simulating Real-World Effectiveness for a New Therapy

Challenge

Our Solution

Results and Impact

Rare Diseases

Extending Randomized Controlled Trials (RCT) Insights to Real-World Outcomes

Challenge

Our Solution

Results and Impact

Data & Digital

Standardizing Disease Identification: From Local Efforts to Scalable Solutions

AI-Powered Registry Identification

Rare Diseases

Standardizing Disease Identification: From Local Efforts to Scalable Solutions

Challenge

Our Solution

Results and Impact

RWD & Registries

AI-Powered Registry Identification

Challenge

Our Solution

Results and Impact

Corporate Development

Optimizing Clinical Strategies through Integrated Evidence Generation Planning

Rescuing Value from Failed Trials to enable Strategic Acquisitions

Optimizing Asset Strategy using Synthetic Control Arms

Accelerating Deal Prospecting through AI-Powered Target Screening

Oncology & Immunology

Optimizing Clinical Strategies through Integrated Evidence Generation Planning

Challenge

Our Solution

Results and Impact

Neurology

Rescuing Value from Failed Trials to enable Strategic Acquisitions

Challenge

Our Solution

Results and Impact

Dermatology

Optimizing Asset Strategy using Synthetic Control Arms

Challenge

Our Solution

Results and Impact

Target Identification

Accelerating Deal Prospecting through AI-Powered Target Screening

Challenge

Our Solution

Results and Impact

Let’s Build Your Success Story

Identifying Drivers of Self-Diagnosis  to Enable OTC Switch

Cardiovascular Diseases

Optimizing Care Pathways  for Heart Failure Patients

Standardizing Disease Identification:  From Local Efforts to Scalable Solutions

Optimizing Clinical Strategies through  Integrated Evidence Generation Planning

Optimizing Asset Strategy using  Synthetic Control Arms

Accelerating Deal Prospecting  through AI-Powered Target Screening

Let’s Build
Your Success Story